Everyday Health on MSN
GLP-1 drugs for obesity: How to switch from the needle to a pill
Learn how to transition from injectable GLP-1s to oral options like Wegovy and Foundayo, with expert advice on dosing, side ...
From narrow volume windows to SGLT2 inhibitors and emerging devices, Drs Kevin Alexander and Sarah Cuddy discuss heart ...
Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the presentation of results ...
While semaglutide has shown impressive results in aiding weight loss, many users may experience a plateau after an initial ...
Doctronic reports that Foundayo, an oral GLP-1 for diabetes, shows promise but lacks long-term safety data beyond 68 weeks; ...
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of new Phase 1 data on DA-1726, a novel dual ...
During the quarter ended March 31, 2026, Baron Health Care Fund® (the Fund) declined 6.97% (Institutional Shares), compared ...
Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, today announced that new clinical data ...
Even though sugars are often framed as simple sources of energy, they also serve as structurally complex and functionally diverse molecules that mediate interactions between organisms.
Health tech companies Wheel and b.well Connected Health are partnering to offer turnkey infrastructure for next-generation AI ...
Topline results from the phase 3 REVITALYZ study show sodium oxybate extended release improves daytime sleepiness in idiopathic hypersomnia.
The Hearty Soul on MSN
People are jumping on a new Ozempic trend that is proving to be effective
Microdosing Ozempic is becoming the newest branch of the GLP-1 conversation, and the appeal is easy to understand. Some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results